BioCentury | Dec 1, 2016
Company News

BromSite sales and marketing update

...low-dose bromfenac, an NSAID, and is delivered via the DuraSite sustained delivery technology from Sun's InSite...
BioCentury | Jul 25, 2016
Company News

Bind Therapeutics, Pfizer deal

...Phase II iNSITE 1 trial in squamous non-small cell lung cancer (NSCLC) and Phase II iNSITE...
BioCentury | Jul 11, 2016
Finance

Shedding red

...Phase II iNSITE 1 trial in squamous non-small cell lung cancer (NSCLC) and Phase II iNSITE...
BioCentury | May 9, 2016
Financial News

QLT withdraws private placement

...raise $20 million. The company proposed the offering last June, when it planned to acquire InSite Vision Inc....
...when the Ranbaxy Inc. subsidiary of Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA, Mumbai, India) acquired InSite...
BioCentury | Apr 18, 2016
Clinical News

BIND-014: Phase II halted

...Bind halted further enrollment in the open-label, international Phase II iNSITE 2 trial evaluating IV BIND-014...
...n=23). Earlier this year, Bind discontinued enrollment in the cholangiocarcinoma and bladder cancer cohorts of iNSITE...
BioCentury | Apr 18, 2016
Clinical News

BIND-014: Updated Phase II data

...in intent-to-treat (ITT) population of the squamous histology cohort of the open-label, international Phase II iNSITE...
...cohort but not the K-Ras ( KRAS )-mutation NSCLC cohort into the second stage of iNSITE...
BioCentury | Apr 18, 2016
Company News

Bind Therapeutics cancer, drug delivery news

...and molecularly targeted therapies. The restructuring follows data from the Phase II iNSITE 1 and iNSITE...
...iNSITE 2. In January, Bind discontinued enrollment in the cholangiocarcinoma and bladder cancer cohorts of iNSITE...
BioCentury | Apr 11, 2016
Analyst Picks & Changes

Analyst picks & changes

...primary endpoint in the iNSITE 1 trial in non-small cell lung cancer (NSCLC), while the iNSITE...
BioCentury | Feb 8, 2016
Clinical News

BIND-014: Completed Phase II enrollment

...of about 40 patients in the squamous histology cohort of the open-label, international Phase II iNSITE...
BioCentury | Feb 8, 2016
Clinical News

BIND-014: Phase II ongoing

...discontinued enrollment in the cholangiocarcinoma and bladder cancer cohorts of the open-label, international Phase II iNSITE...
Items per page:
1 - 10 of 235
BioCentury | Dec 1, 2016
Company News

BromSite sales and marketing update

...low-dose bromfenac, an NSAID, and is delivered via the DuraSite sustained delivery technology from Sun's InSite...
BioCentury | Jul 25, 2016
Company News

Bind Therapeutics, Pfizer deal

...Phase II iNSITE 1 trial in squamous non-small cell lung cancer (NSCLC) and Phase II iNSITE...
BioCentury | Jul 11, 2016
Finance

Shedding red

...Phase II iNSITE 1 trial in squamous non-small cell lung cancer (NSCLC) and Phase II iNSITE...
BioCentury | May 9, 2016
Financial News

QLT withdraws private placement

...raise $20 million. The company proposed the offering last June, when it planned to acquire InSite Vision Inc....
...when the Ranbaxy Inc. subsidiary of Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA, Mumbai, India) acquired InSite...
BioCentury | Apr 18, 2016
Clinical News

BIND-014: Phase II halted

...Bind halted further enrollment in the open-label, international Phase II iNSITE 2 trial evaluating IV BIND-014...
...n=23). Earlier this year, Bind discontinued enrollment in the cholangiocarcinoma and bladder cancer cohorts of iNSITE...
BioCentury | Apr 18, 2016
Clinical News

BIND-014: Updated Phase II data

...in intent-to-treat (ITT) population of the squamous histology cohort of the open-label, international Phase II iNSITE...
...cohort but not the K-Ras ( KRAS )-mutation NSCLC cohort into the second stage of iNSITE...
BioCentury | Apr 18, 2016
Company News

Bind Therapeutics cancer, drug delivery news

...and molecularly targeted therapies. The restructuring follows data from the Phase II iNSITE 1 and iNSITE...
...iNSITE 2. In January, Bind discontinued enrollment in the cholangiocarcinoma and bladder cancer cohorts of iNSITE...
BioCentury | Apr 11, 2016
Analyst Picks & Changes

Analyst picks & changes

...primary endpoint in the iNSITE 1 trial in non-small cell lung cancer (NSCLC), while the iNSITE...
BioCentury | Feb 8, 2016
Clinical News

BIND-014: Completed Phase II enrollment

...of about 40 patients in the squamous histology cohort of the open-label, international Phase II iNSITE...
BioCentury | Feb 8, 2016
Clinical News

BIND-014: Phase II ongoing

...discontinued enrollment in the cholangiocarcinoma and bladder cancer cohorts of the open-label, international Phase II iNSITE...
Items per page:
1 - 10 of 235